TBCD and cancer: In addition, we speculate that SSD1 may be a potential target for modifying the rate of ploidy changes and genome stability in commercial settings, such as the large-scale production of economically important metabolites, and in clinical scenarios, such as the treatment of pathogenic fungal diseases and some cancers.